Igyxos Biotherapeutics, a French biotechnology company, has been awarded a grant of EUR 5.7 million by the French government to boost the development of its innovative monoclonal antibody treatment for infertility. The funding will support Phase 2 clinical trials in France and Europe for IGX12, a first-of-its-kind monoclonal antibody developed to boost the potency of follicle stimulating hormone (FSH), a crucial hormone involved in female and male gametogenesis. The treatment aims to address both male and female infertility, with male infertility accounting for nearly half of all cases. The company plans to advance IGX12 through Phase 2 clinical trials in both men and women, with a long-term goal of introducing a new therapeutic option for couples with fertility challenges. The company expects to release the latest results from its Phase 1 clinical trial in the fourth quarter of 2025.